Study Case:
Effects of Oxyglobin® on Complete Blood Count and Blood
Chemistry
Jeff Legato,
DVM; Heather L. Tarpley, DVM; Holly A. Moore, DVM; Kenneth S. Latimer,
DVM, PhD
Class of 2005 (Legato)
and Department of Pathology (Tarpley, Moore, Latimer,), College of
Veterinary Medicine, University of Georgia, Athens, GA 30602-7388

Signalment: Canine,
Golden retriever, 9-year-old, male
Presenting
problems: Presented for severe anemia and thrombocytopenia
diagnosed by the referring veterinarian. Previously treated by
the referring veterinarian with doxycycline, prednisone, and Oxyglobin®.
Physical
examination findings: Depression and lethargy, pale skin
and mucous membranes, slow capillary refill time (3 seconds), tachycardia
(HR=180 bpm), tachypnea (RR=45 bpm), hypothermia (T=95.6°F), and
epistaxis.
Laboratory
Data:
| Complete
Blood Count |
|
Day
1 |
Day
3 |
Day
6 |
Units |
Reference
Interval |
HCT |
6.2
(L) |
9
(L) |
8.5
(L) |
% |
30.0-45.0 |
RBC |
ND |
NDO |
1.43
(L) |
X 106 cells/m
l |
5.0-10.0 |
HGB |
2
(L) |
5.3
(L) |
3.4
(L) |
g/dL |
9.8-15.4 |
MCV |
ND |
52.6 |
55.4
(H) |
fl |
39-55 |
MCH |
ND |
NDO |
23.9
(H) |
pg |
13.0-17.0 |
MCHC |
32.3 |
NDO |
40
(H) |
g/dL |
30-36 |
PLT |
80
(L) |
ND |
160
(L) |
X
103 plts/m l |
211-621 |
RETICS |
1.6
(H) |
0.2 |
1.0 |
% |
0.0-1.0 |
WBC |
6.3 |
12.3 |
14.2
(H) |
X
103 cells/m l |
5.1-13.0 |
| Biochemistry
Data |
|
Day
1a |
Day
3b |
Day
6b |
Units |
Reference
Interval |
| BUN |
55.5
(H)` |
146
(H) |
78
(H) |
mg/dL |
20.0-34.0 |
| Creat |
1.17 |
NDO |
NDO |
mg/dL |
0.9-2.1 |
| TP |
8.73
(H) |
NDO |
ND |
g/dL |
6.0-7.7 |
| Alb |
ND |
NDO |
ND |
g/dL |
3.0-4.3 |
| Alk
Phos |
22 |
NDO |
ND |
U/L |
0-50 |
| ALT |
34 |
36 |
372
(H) |
U/L |
31-104 |
| Glucose |
170.7
(H) |
144
(H) |
115 |
mg/dL |
62-122 |
| Na |
ND |
154 |
158
(H) |
mmol/L |
149-156 |
| K |
ND |
4.2 |
3.3
(L) |
mmol/L |
3.6-6.0 |
| Cl |
ND |
113 |
115 |
mmol/L |
113-125 |
| HCO3- |
ND |
NDO |
ND |
mmol/L |
13-20 |
| AG |
ND |
NDO |
ND |
mmol/L |
17-27 |
| Ca |
ND |
8.8
(L) |
8.8
(L) |
mg/dL |
9.0-10.8 |
| P |
ND |
NDO |
ND |
mg/dL |
3.2-6.2 |
| Mg |
ND |
NDO |
ND |
mg/dL |
1.7-2.6 |
| Chol |
ND |
NDO |
ND |
mg/dL |
71-147 |
| Bilirubin |
ND |
NDO |
ND |
mg/dL |
<0.1 |
A
= Type of analyzer used is unknown.
B = Hitachi
912 chemistry Analyzer used.
ND = Not
done
NDO = Not
done because of Oxyglobin administration
Day 1 = Tests
performed by RDVM prior to treatment
Days 3 and
6 = Tests performed at the veterinary teaching hospital.
NB. Reference
intervals for laboratory data on Day 1 are unknown; reference
intervals for Days 3 and 6 are values established by the clinical
pathology laboratory at the UGA College of Veterinary Medicine. |
Problems
-
1. Severe
anemia
a. Severe,
normochromic, nonregenerative anemia (Days 1 and 3)
with marked thrombocytopenia.
b. Severe,
macrocytic, hyperchromic, nonregenerative anemia with moderate
thrombocytopenia (Day 6).
The corrected reticulocyte
percentages are 0.20, 0.04, and 0.19 for days 1,3, and 6, respectively.
Based on these percentages, the anemia is considered nonregenerative
though very slight improvement occurred between days 3 and 6. The
cause of anemia is unknown. The combination of anemia with thrombocytopenia
could be observed with marked blood loss (e.g., hemorrhage),
immune-mediated destruction of both erythrocytes and platelets (Evans
syndrome), or ineffective production of both cell types. Epistaxis
was noted in this case and could be attributable to severe thrombocytopenia
(due to the causes listed above as well as disseminated intravascular
coagulation) or other coagulopathy. Cases of acute blood loss and
immune-mediated destruction of erythrocytes are often associated
with an elevated MCV and a decreased MCHC due to the presence of
a marked regenerative response (and the release of polychromatophilic
cells or reticulocytes). Chronic blood loss may lack signs of regeneration
and MCV and MCHC are either within or below reference intervals.
Oxyglobin® administration typically results in decreased
hematocrit values due to dilution of erythrocytes. Total hemoglobin
concentration, the summation of hemoglobin within erythrocytes and
plasma hemoglobin, is usually increased since Oxyglobin® is
extracellular hemoglobin that is infused into the vascular system.
In this case, an approximate 2.5-fold increase in hemoglobin concentration
was observed on Day 3, though this most likely is falsely elevated
due to dehydration (see "azotemia" below). The slight increase
in MCV may be attributable to the slight increase in reticulocytes
observed on Day 6 (in comparison to Day 3). Increases in both MCH
and MCHC are most likely due to the assumption that all measured
hemoglobin is intracellular, which is not the case with Oxyglobin® administration.
The increase in platelet concentration may be attributable to corticosteroid
therapy, which decreases platelet destruction and antibody production,
may stimulate platelet production, and may increase capillary resistance
to hemorrhage.
2. Mild
leukocytosis (day 6). General
causes of leukocytosis include physiologic mechanisms (e.g., fear,
excitement, or struggling during venipuncture), stress with endogenous
cortisol release, or an increased tissue demand for neutrophils. The
precise cause of the leukocytosis is undetermined.
3. Azotemia
with hyperproteinemia. Azotemia
is observed on Days 1, 3, and 6, with the highest value being
on Day 3. Measurement
of BUN is not affected by the presence of Oxyglobin® regardless
of instrumentation; creatinine values may be incorrect for
the majority of analyzers used. Considerations for azotemia
include prerenal,
renal, and postrenal causes; a urine specific gravity would
be helpful in accurately determining the basic etiology of
the azotemia, but
it is unknown in this case. A creatinine value within the reference
interval and an elevated total protein on Day 1 increases suspicion
of prerenal causes such as hypovolemia /dehydration. Hyperproteinemia
would be better evaluated if the albumin concentration were
known. Serum protein measurements are often increased with
Oxyglobin;® peak
protein concentrations of 9.9 to 14.6g/dL may be observed at
the recommended dose. The measurement on Day 1 is prior to
Oxyglobin® therapy.
4. Increased
alanine aminotransferase. With recommended
dosages of Oxyglobin,® ALT measurement remains accurate
when Hitachi analyzers are used. However, other analyzers may give
invalid results. Hitachi instrumentation was used on Days 3 and 6
(instrumentation is unknown for Day 1). An increase in ALT is observed
on Day 6 which most likely is attributable to hepatocellular injury
that can occur secondary to tissue hypoxia resulting from severe
anemia and possible dehydration.
5. Mild
hyperglycemia. Glucose
concentration can be accurately measured with Hitachi analyzers
after Oxyglobin® administration.
The elevations observed are mild and could be attributable to postprandial
measurement or mild stress.
6. Mild
hypocalcemia. Measurement
of calcium concentration is unaffected by Oxyglobin® administration
for nearly all analyzers. Exclusion of pseudohypocalcemia cannot
be done without an albumin measurement. Values for albumin may
be invalid regardless of the analyzer used after Oxyglobin® treatment.
Case Summary
- This dog had severe
anemia that was treated with the administration of Oxyglobin.® This
patient only showed minor improvement clinically or in erythrocytic
parameters five days post-treatment with Oxyglobin.® The
patient subsequently was euthanized. Necropsy and histopathology
failed to demonstrate evidence of an adequate erythropoietic response
in the bone marrow. These were consistent with a terminal hemolytic
anemia.
Oxyglobin®,
a product of the Biopure Corporation, is a hemoglobin-based oxygen
carrier (HBOC) that has been used to successfully treat anemia of
various causes in dogs. Oxyglobin® helps to stabilize
anemic dogs, providing oxygen-carrying support and thus reduces clinical
signs until the patients bone marrow is able to regenerate
erythrocytes. When given at the recommended dose, Oxyglobin® has
a half-life of 18-26 hours and is expected to be cleared from the
plasma within 4-5 days.
Different analyzers
and lists of tests whose results are unaffected by the presence of
Oxyglobin® are shown in the Table A below. Experimental
data of human blood samples concerning the effects of a hemoglobin-based
oxygen-carrier (HBOC-201; now Oxyglobin®) on CBC variables
and WBC differential variables measured with the Cell-Dyn 3500 indicated
no interference in the following measured or calculated variables:
HCT, RBC count, platelet count, WBC count, MCV, MPV, RDW, and individual
leukocyte concentrations. Hemoglobin concentration is accurate as
long as it is measured and not based on a calculation using the red
blood cell count.
Presence of Oxyglobin® essentially
causes no interference with sodium, potassium, and chloride determinations,
which are usually measured by ion-specific electrodes (including
Hitachi analyzers). Creatinine may be affected depending on the analytical
method used; enzymatic test methods are unaffected whereas colorimetric
tests are inaccurate. Analytes that are measured on the Hitachi 912
by colorimetric methods include total protein, albumin, ALT, AST,
GGT, LDH, ALP, amylase, magnesium, phosphorus, direct and total bilirubin.
Following Oxyglobin® administration, total protein, albumin,
amylase, magnesium, phosphorus, direct and total bilirubin may be
inaccurate. However, ALT, AST, GGT, LDH, ALP activities are measured
at a wavelength of 340 nm and may be reasonably accurate. In summary,
Oxyglobin® does not interfere with most analytes of the
highest urgency in the critical care setting.
Table
A. Accurate analytes by instrumentation at plasma hemoglobin
= 4.0 g/dL*, Biopure Corporation, 11 Hurley Street, Cambridge,
MA 02141, <www.biopure.com>.
Though a urinalysis
is not reported here, tests on the urine dipstick, such as pH, glucose,
ketones, and protein, are inaccurate as long as the urine is grossly
discolored because these tests are colorimetric. The urine sediment
examination and urine specific gravity are not affected by the presence
of Oxyglobin®.
References
1. Belgrave RL,
Hines MT, Keegan RD, Wardrop KJ, Bayly WM, Sellon DC: Effects of
a polymerized ultrapurified bovine hemoglobin blood substitute administered
to ponies with normovolemic anemia. J Vet Intern Med 16:396-403,
2000.
2. Callan MB, Rentko
VT: Clinical application of a hemoglobin-based oxygen-carrying solution.
Vet Clin North Am Small Anim Pract 33: 1277-1293, 2003.
3. Clinical Reference
Guide: Oxyglobin Solution, Brochure, published by Biopure Corp, 11
Hurley St, Cambridge, MA 02141, www.biopure.com .
4. Kirby R, Duffy
TC: Resuscitation in gastric dilatation-volvulus syndrome. Compend
Cont Educ Pract Vet, Suppl 23:8-11, 2001.
5. Latimer KS,
Mahaffey EA, Prasse KW (eds): Duncan & Prasses Veterinary
Laboratory Medicine: Clinical Pathology, 4th ed. Ames, Iowa State
Press, 2003.
6. Mott J, Crystal
MA: Treating flea anemia with Oxyglobin®. Compend Cont
Educ Pract Vet, Suppl 21(H): 11-16, 1999.
7. Plumb DC: Veterinary
Drug Handbook, 4th ed., Iowa State Press, 2003, p. 960.
8. Various authors,
2002, IMHA: New Perspectives on a challenging disease, Pamphlet sponsored
by Biopure Corp, Published by Thomson Veterinary Healthcare Communication,
Lexena, KS, pp. 1-16.
9. Ma A, Monk TG,
Goodnough LT, McClellan A, Gawryl M, Clark T, Moreira P, Keipert
PE, Scoot MG: Effect of hemoglobin- and perflubron-based oxygen carriers
on common clinical laboratory tests. Clin Chem 43:1732-1737, 1997.
10. Callas DD,
Clark TL, Moreira PL, Lansden C, Gawryl MS, Kahn S, Bermes EW Jr:
In vitro effects of a novel hemoglobin-based oxygen carrier on routine
chemistry, therapeutic drug, coagulation, hematology, and blood bank
assays. Clin Chem 43:1744-48, 1997.
11. Rentko VT,
Sharpe TA: Red blood cell substitutes. In: Feldman BF, Zinkl
JG, Jain NC (eds): Schalms Veterinary Hematology, 5th ed. Philadelphia,
Lippincott Williams and Wilkins, 2000, pp. 874-877.
Acknowledgement
"Companion",
the image of the Golden Retriever is from the Art
Gallery at the website
of Dino the Golden Retriever. |